Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT02110147
- Locations
- 🇺🇸
Children's Hospital of Michigan - Specialty Center Detroit, Detroit, Michigan, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination
- Conditions
- Toxicity Due to Chemotherapy
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Wellstat Therapeutics
- Registration Number
- NCT01432301
Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110864
- Locations
- 🇺🇸
Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
🇺🇸Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
🇺🇸Genesis Research International, Longwood, Florida, United States
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00110851
- Locations
- 🇺🇸
Phoenix Internal Medicine Associates, Waterbury, Connecticut, United States
🇺🇸University Clinical Research-DeLand, DeLand, Florida, United States
🇺🇸Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
- Conditions
- Drug/Agent Toxicity by Tissue/OrganPancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 250
- Registration Number
- NCT00024427
- Locations
- 🇺🇸
Brookwood Medical Center, Birmingham, Alabama, United States
🇺🇸Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
- Conditions
- Solid Tumors
- First Posted Date
- 2002-09-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT00044785
- Locations
- 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States